Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
*Consult with a medical professional before incorporating a new diet or supplement into your routine.
This review synthesizes basic science and translational evidence supporting glucagon-like peptide-1, glucagon-like peptide-2, and dipeptidyl peptidase-IV inhibition as emerging therapeutic concepts in inflammatory bowel disease
The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes
enrolled 3731 patients without T2DM (BMI 27 kg/m 2 or 30 kg/m 2 ) and gave LIR 3mg daily subcutaneous injection
In drug repositioning it is crucial to understand the disease-drug relationship, for this reason, there are several approaches to address the problem: In silico approaches: in this type of approach, various public databases, clinical trials, and bioinformatic systems are used to identify drug-target interactions (Ekins et al., 2007)
